An Evaluation of Two Years of Clinical Experience with Ketoconazole

Symoens, J.; Moens, M.; J, Dom; Scheijgrond, H.; Dony, J; Schuermans, V.; Legendre, R.; Finestine, N.

doi:10.1093/clinids/2.4.674

Cited by 123 publications

(23 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The decision concerning initiation of therapy for fungal infections poses a major problem for the attending physician; the number of effective antifungal drugs is small, and often these drugs possess marked toxicity to the host (2,16,25). Although ketoconazole has been suggested as a rather nontoxic drug for general use in systemic fungal infections, a complete clinical evaluation is not available (10,23). It is clear that specific and nontoxic antifungal drugs are needed.…”

mentioning

confidence: 99%

Polyoxin D inhibits growth of zoopathogenic fungi

Becker¹,

Covert²,

Shenbagamurthi³

et al. 1983

Antimicrob Agents Chemother

View full text Add to dashboard Cite

We demonstrated that polyoxin D at millimolar concentrations caused marked morphological alterations of the human pathogens Candida albicans and Cryptococcus neoformans. C. albicans incubated in the presence of this drug grew in long chains that were severely swollen. Polyoxin D inhibited the growth of C. neoformans and killed cells of both the yeast and the hyphal phase of C. albicans. These observations give the first evidence that polyoxin antibiotics can kill zoopathogenic fungi.

show abstract

mentioning

confidence: 99%

Polyoxin D inhibits growth of zoopathogenic fungi

Becker¹,

Covert²,

Shenbagamurthi³

et al. 1983

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…It was introduced in clinical practice for the treatment of systemic fungal infections in the early 1980s (16,17). In fungi, it inhibits the synthesis of ergosterol, a cell membrane sterol.…”

Section: Currently Available Steroidogenesis Inhibitorsmentioning

confidence: 99%

“…For optimal absorption, the presence of an acidic gastric environment is necessary (16). Achlorhydria, administration on an empty stomach or concurrent use of antacids and proton pump inhibitors may lead to reduced absorbance and treatment failure (16,27,36).…”

Section: Currently Available Steroidogenesis Inhibitorsmentioning

confidence: 99%

THERAPY OF ENDOCRINE DISEASE: Steroidogenesis enzyme inhibitors in Cushing's syndrome

Daniel

Newell‐Price

2015

European Journal of Endocrinology

111

View full text Add to dashboard Cite

Steroidogenesis enzyme inhibitors are the mainstay of medical therapy in Cushing's syndrome (CS). Ketoconazole (KTZ) and metyrapone are the most commonly used agents. Although there is considerable experience of their use in individual specialist centres, these drugs have not been rigorously tested in prospective clinical trials. Clinicians face uncertainties and concerns with respect to the safety profile of these agents, and best means to monitor effect. We review steroidogenesis inhibitors in the management of CS, including older agents (KTZ, metyrapone, etomidate and mitotane) and those currently under development (LCI699, non-racemic KTZ), and offer a practical approach for their use in clinical practice.

show abstract

“…91/2 49 Local antimycotics, amphothericin B, 5-fluorocytosine, clotrimazole, miconazole, transfer factor and transplantation of 11 35 bone marrow or fetal thymus have been used with variable success, and frequently with undesirable side effects. Lesions usually relapsed when the drugs were withdrawn [4,10,16 Recently promising results using long-term oral therapy with ketoconazole, a new imidazole derivative, were reported in children and adults [7,12,15,24,26,27,29]. We present two children with CMC successfully treated with long-term intermittent ketoconazole therapy, which may by the ideal mode of treatment.…”

Section: Othertherapymentioning

confidence: 99%

Intermittent ketoconazole therapy of chronic mucocutaneous candidiasis in childhood

et al. 1982

View full text Add to dashboard Cite

We report the clinical and laboratory findings in two children with chronic mucocutaneous candidiasis (CMC) treated successfully with intermittent long-term ketoconazole therapy. Both had chronic infection of the nails, skin and mucous membranes with positive cultures for candida. Both were resistant to multiple local and systemic antifungal agents. After institution of ketoconazole therapy there was a dramatic improvement with clearing of the oral (one week), skin (two months) and nail lesions (5 months). After 8 months the drug was stopped and clinical remission persisted for 10 and 7 months respectively. Relapse of oral candidiasis was treated with a short course of ketoconazole (4-16 weeks) leading to complete healing of the lesions. Clinical improvement was not related to an amelioration in lymphocyte transformation. There was no change in the progressive deterioration of the lymphocyte responses to candida antigen which was probably due to persisting candida cell wall components (e.g. mannan).

show abstract

An Evaluation of Two Years of Clinical Experience with Ketoconazole

Cited by 123 publications

References 0 publications

Polyoxin D inhibits growth of zoopathogenic fungi

Polyoxin D inhibits growth of zoopathogenic fungi

THERAPY OF ENDOCRINE DISEASE: Steroidogenesis enzyme inhibitors in Cushing's syndrome

Intermittent ketoconazole therapy of chronic mucocutaneous candidiasis in childhood

Contact Info

Product

Resources

About